Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds

Figure 5

SC403 significantly increases DHA levels in both plasma and red blood cells (RBC) membrane in a piglet model of Short Bowel Syndrome (SBS). After a 70% mid-jejune-ileal resection, neonatal piglets were fed with 1 g/kg/day of DHA EE or 1 g/kg/day of DHA EE + ALT® (SC403) and the percentage of DHA was measured in blood. The comparison of DHA plasma levels in DHA (blue) vs. SC403 (red) treated SBS piglets reveals a statistically significant increase in DHA in SC403-treated piglets, both in plasma (a) and red blood cells membranes (b) 8 days after intervention (SEM ± SE) as compared with the piglets treated with DHA alone. : p<0.005.

(a)

(b)